Company intelligence / Profile preview

Nanjing Yoko Biomedical Co., Ltd.

Ownership: Private
Development stage: Phase 3

Overview

Nanjing Yoko Biomedical is an innovative Chinese biopharma focused on developing and commercializing new drugs with indigenous intellectual property. The company has achieved approval for antibiotics targeting infectious diseases and is advancing oncology assets into early-phase trials. It also pursues biosimilars through its affiliates/subsidiaries.[5][3][4]

Therapeutic areas: OncologyCardiovascularNeurologyInfectious Diseases
Modalities: Small molecules[1]Monoclonal antibodies[4]Biosimilars[4]
Industry: Biotech

Drug pipeline

2 assets

tafetinib

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Nanjing Yoko Biomedical Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nanjing Yoko Biomedical Co., Ltd..

Explore the full profile